Pure Global
NCT06351605

A Registry Study to Assess Photobiomodulation in Dry Age-Related Macular Degeneration (EUROLIGHT) (EUROLIGHT)

A Multi-Center Registry Study to Assess the Safety and Effectiveness of Photobiomodulation in Participants With Dry Age-Related Macular Degeneration (EUROLIGHT)
LumiThera, Inc.·ClinicalTrials.gov·device·Device trialRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Dry Age-related Macular Degeneration
Drug/Device/Intervention
Valeda Light Delivery System
Study type
Observational
Intervention type
device
Sponsor & location
Primary sponsor
LumiThera, Inc.
Location
Oslo, Norway
Timeline & enrollment
Phase
N/A
Start date
Sep 01, 2023
End date
Dec 01, 2026
Enrollment
500 participants
Primary outcome

Best-Corrected Visual Acuity (BCVA)

Summary

The EUROLIGHT study is being conducted to collect real life data for the safety and
 effectiveness of PBM in dry AMD, in routine clinical practice both retrospectively and
 prospectively.

ICD-10 classifications
Peripheral retinal degenerationCorneal degenerationHereditary retinal dystrophyOptic atrophy in diseases classified elsewhereDisorders of choroid and retina
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06351605
Type
Device Trial
About this record

Access comprehensive clinical trial information for NCT06351605 through Pure Global AI's free database. This phase not specified trial is sponsored by LumiThera, Inc. and is currently Recruiting. The study focuses on Dry Age-related Macular Degeneration. Target enrollment is 500 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.